I hate to rain on the parade but it looks UHC is removing Vascepa and GV from coverage. Might be just a precaution until the suits are settled or it might be a salvo from the health insurance industry in response to AMRN’s suit against HN. GSK/Teva and AMRN/Hikma/HN cases have shed light on infringement issues and muddied the waters for payers. I don’t see this as good news for scripts or near term growth.
Sleven, I reread the link thought provide and it’s only referring to the UHC Commercial plans. Still not good but I’m hoping Vascepa is still on their Medicare plans and others.